使用小分子准von Hippel-Lindau E3泛素结合酶来破坏VHL/HIF-1α相互作用
Dennis L Buckley1, Inge Van Molle, Peter C Gareiss
1Department of Chemistry, Yale University, New Haven, Connecticut 06511, United States.
Journal of the American Chemical Society
|February 29, 2012
概括
研究人员开发了第一种小分子抑制剂,用于希佩尔-林道 (VHL) 蛋白,这是癌症和贫血的关键标. 这一突破模仿了天然基质,为新的VHL向治疗铺平了道路.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 在蛋白质降解过程中,E3无素连接酶至关重要,由于其特异性,它们是有吸引力的药物标.
- 开发E3链酶的小分子抑制剂具有挑战性,因为它涉及向蛋白质-蛋白质相互作用.
研究的目的:
- 为了产生第一个针对希佩尔-林道 (VHL) 蛋白的小分子抑制剂,这是一个关键的E3结合酶基质识别子单元.
- 通过确定与该化合物结合的VHL的晶体结构来验证抑制剂的机制.
主要方法:
- 合理的药物设计被用来创建小分子抑制剂.
- 通过X射线晶体学,获得了VHL-抑制剂复合物的结构.
主要成果:
- 首个针对VHL的小分子抑制剂成功生成.
- 晶体结构显示,该抑制剂模仿HIF-1α的结合,这是已知的VHL基质.
- 该抑制剂显示出治疗开发的潜力.
结论:
- 这项研究提出了一种新的小分子抑制剂VHL,在癌症,贫血和缺血等疾病中是一个重要的目标.
- 这些发现为未来开发改进的VHL向治疗方法提供了结构性基础.
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...